Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million

Core Viewpoint - Azitra, Inc. has announced a private placement financing of up to approximately $31.4 million, which includes an initial funding of about $10.5 million and an additional potential $20.9 million through the exercise of warrants, aimed at advancing its innovative protein and peptide research programs for the cosmetic and cosmeceutical markets [1][3]. Financing Details - The financing involves a securities purchase agreement with institutional investors, including Stonepine Capital and Nantahala Capital, and is expected to close around March 20, 2026, pending customary closing conditions [1][2]. - The company will issue 10,470 shares of Series A convertible non-redeemable preferred stock at a price of $1,000 per share, along with Series B and Series C warrants to purchase up to 85,101,201 shares of common stock [4][5]. Market Potential - The market for biotech-oriented cosmetic ingredients was valued at $2.3 billion in 2024 and is projected to grow to $3.7 billion by 2030, indicating significant growth opportunities for Azitra's new initiatives [3]. Product Development Focus - Azitra is focusing on developing proprietary filaggrin protein and peptide technologies aimed at addressing skin issues such as fine lines, wrinkles, and eczema-like rashes, leveraging its expertise in skin science and microbial genetic engineering [4][9]. - The company’s lead program, ATR-12, targets Netherton syndrome, a rare skin disease, while ATR-04 addresses EGFR inhibitor-associated rash, with both programs utilizing engineered strains of S. epidermidis [9]. Use of Proceeds - The initial net proceeds from the financing will be allocated towards research and development, general corporate expenses, and working capital needs [7].